ABSTRACT
The aim of this study was to elucidate whether fecoflowmetry (FFM) could evaluate more detailed evacuative function than anorectal manometry by comparing between FFM or anorectal manometric findings and the clinical questionnaires and the types of surgical procedure in the patients who received anal-preserving surgery. Fifty-three patients who underwent anal-preserving surgery for low rectal cancer were enrolled. The relationships between FFM or the manometric findings and the clinical questionnaires and the types of procedure of anal-preserving surgery were evaluated. There were significant differences between FFM markers and the clinical questionnaire and the types of the surgical procedure, whereas no significant relationship was observed between the manometric findings and the clinical questionnaire and the types of the surgical procedure. FFM might be feasible and useful for the objective assessment of evacuative function and may be superior to manometry for patients undergoing anal-preserving surgery.
Subject(s)
Anal Canal/physiopathology , Defecation/physiology , Fecal Incontinence/diagnosis , Postoperative Complications/diagnosis , Rectal Neoplasms/surgery , Rectum/physiopathology , Adult , Aged , Aged, 80 and over , Anal Canal/surgery , Fecal Incontinence/etiology , Fecal Incontinence/physiopathology , Female , Health Status Indicators , Humans , Male , Manometry , Middle Aged , Postoperative Complications/physiopathology , Postoperative Period , Rectal Neoplasms/physiopathology , Rectum/surgery , Surveys and Questionnaires , Treatment OutcomeABSTRACT
AIM: To investigate the potential involvement of claudin-1 (CL-1) in the tumorigenesis of rectal cancer by analyzing the correlation between CL-1 expression, clinicopathological factors and prognosis. PATIENTS AND METHODS: Rectal cancer tissue specimens from 306 patients that had undergone surgical treatment were evaluated using immunohistochemical analysis for expression of CL-1 and correlated with clinicopathological factors. RESULTS: A reduced expression of CL-1 (less than 30% of tumor cells strongly, positively stained) correlated significantly with poor prognosis in stage II and III rectal cancer. Moreover, the expression levels of CL-1 correlated significantly with tumor differentiation and perineural invasion (p=0.037 and 0.009, respectively). However, no significant differences were detected between the expression levels of CL-1 and other clinicopathological factors. CONCLUSION: Loss of claudin-1 expression is a strong predictor of disease recurrence and poor patient survival in stage II and III rectal cancer.
Subject(s)
Adenocarcinoma/metabolism , Membrane Proteins/physiology , Neoplasm Proteins/physiology , Rectal Neoplasms/metabolism , Adenocarcinoma/chemistry , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Carcinoembryonic Antigen/analysis , Cell Differentiation , Cell Membrane/chemistry , Claudin-1 , Cytoplasm/chemistry , Down-Regulation , Female , Humans , Lymphatic Metastasis , Male , Membrane Proteins/analysis , Membrane Proteins/biosynthesis , Middle Aged , Neoplasm Invasiveness , Neoplasm Proteins/analysis , Neoplasm Proteins/biosynthesis , Neoplasm Staging , Prognosis , Proportional Hazards Models , Rectal Neoplasms/chemistry , Rectal Neoplasms/mortality , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , RecurrenceABSTRACT
BACKGROUND: Expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) has been shown to increase in colorectal cancer. We examined the correlation between expression of IGF-1 and IGF-1R and clinicopathological factors in colorectal cancer. PATIENTS AND METHODS: A prospective study was conducted of 210 colorectal cancer patients that underwent resection from January 2002 to December 2004. The clinicopathological data was correlated to expression of IGF-1 and IGF-1R obtained from immunohistochemical analysis. Statistical analysis was carried using univariate and multivariate analysis. RESULTS: IGF1 and IGF-1R staining was positive in 169 (80%) and 139 (66%) cases, respectively. Univariate and multivariate analyses showed significant correlation between expression of IGF-1 and tumor size (p=0.0024), and depth of invasion (p=0.0147). While IGF-1R was significantly correlated to tumor size and depth of invasion in univariate analysis, only tumor size (p=0.0658) had a strong association in multivariate analysis. CONCLUSION: Expression of IGF-1 and IGF-1R seems to increase with tumor size in colorectal cancer.
Subject(s)
Adenocarcinoma/metabolism , Colorectal Neoplasms/metabolism , Gene Expression Regulation, Neoplastic , Insulin-Like Growth Factor I/biosynthesis , Neoplasm Proteins/biosynthesis , Receptor, IGF Type 1/biosynthesis , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Female , Humans , Insulin-Like Growth Factor I/genetics , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Neoplasm Proteins/genetics , Prospective Studies , Receptor, IGF Type 1/genetics , Tumor BurdenABSTRACT
BACKGROUND: Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients with UC. PATIENTS AND METHODS: A total of 42 patients with UC underwent surgical treatment from January 2001 until October 2010 at Kurume University Hospital. The patient details, preoperative therapy, operative indication and complications were obtained from our prospective database. Univariate, multivariate analysis and tree model were used for statistical analysis. RESULTS: In patients who received LCAP before surgery, CRC was significantly less frequent (p=0.0321). CRC incidence following LCAP increased when the disease period from diagnosis of UC exceeded 133 months. Multivariate analysis showed that the odds for undergoing LCAP were significantly higher (p=0.0305) in those cases with a total dose of steroid more than 2.57 g. CONCLUSION: LCAP may suppress CRC in UC patients.
